Table 2d.

Success/positive rates of humoral vaccination-related de novo immune response dependent on immunosuppression number, type or vaccine type at T2.

Factors	category	DP	KTR	MP
Total Numbers	n	1136	368	144
Immunosuppressive drugs	n /%	63 / 6	367 / 99•8	1 / 0•7
No IS drug	% of group number	96% of 1048	100% of 1	n.a.
One IS drug	% of group number	78% of 37	84% of 19	n.a.
Two IS drugs	% of group number	62% of 13	43% of 180	n.a.
Three IS drugs	% of group number	n.a.	35% of 128	n.a.
CS	% of group number	82% of 28	n.a.	n.a.
CS/CNI	% of group number	n.a.	56% of 25	n.a.
CNI/MMF-MPA	% of group number	n.a.	39% of 123	n.a.
CNI/mTOR-I	% of group number	n.a.	38% of 13	n.a.
CS/CNI/MMF-MPA	% of group number	n.a.	34% of 102	n.a.
CS/CNI/mTOR-I	% of group number	n.a.	50% of 12	n.a.
Belatacept alone or in a combination	% of group number	n.a.	19% of 16	n.a.
Vaccine Type	% of group number	95% of 1136	42% of 333	99% of 134
BNT162b2 mRNA	% of group number	88% of 200*	26% of 99*	97% of 39
mRNA-1273	% of group number	97% of 936	49% of 234	99% of 95

MP = Medical Personnel; DP = Dialysis Patients; KTR = Kidney Transplant Recipient; IS means immunosuppression. CNI = Calcineurin-Inhibitor; MMF-MPA = mycophenolate mofetil or mycophenolic acid; mTOR-I = mTOR-inhibitors; CS = glucocorticosteroids; T2 = 8 weeks after first vaccination.

Vaccination response rates in drug combinations of less than 10 patients were reported as n.a.;.

^⁎statistical significance using p < 0•001 compared to other vaccine type;.